korean semaglutide New obesity drug Mounjaro launches in Korea — is it worth switching from Wegovy? Korea weighs GLP-1 misuse label

doi: 10.3389/fbioe.2023.1279270 Received 17 August 2023 Accepted 17 October 2023 Published 30 October 2023 Volume 11 - 2023 Edited by Balaram Mohapatra, Gujarat Biotechnology Research Centre (GBRC), India Reviewed by Y

"My confidence has increased a lot," she said

In addition, STEP HFpEF-DM, another trial in obese adults with HFpEF and type 2 diabetes, is expected to be completed in the fourth quarter of this year

Tirzepatide has shown liver fat reduction in studies, but no specific MASH trial data with histological endpoints comparable to survodutide

From a therapeutic perspective, future efforts should focus on identifying and validating novel ferroptosis regulators, particularly those targeting non-canonical pathways

Weight loss with semaglutide is typically gradual and sustainable